Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Medicenna Therapeutics Corp.
  6. Summary
    MDNA   CA58490H1073

MEDICENNA THERAPEUTICS CORP.

(MDNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
3.14(c) 3.08(c) 3.2(c) 3.06(c) 3.16 Last
20 047 21 353 41 161 48 251 27 691 Volume
-3.38% -1.91% +3.90% -4.38% +3.27% Change
More quotes
Estimated financial data (e)
Sales 2022 0,13 M 0,10 M 0,10 M
Net income 2022 -24,9 M -19,5 M -19,5 M
Net Debt 2022 - - -
P/E ratio 2022 -6,73x
Yield 2022 -
Sales 2023 4,25 M 3,32 M 3,32 M
Net income 2023 -24,4 M -19,1 M -19,1 M
Net Debt 2023 - - -
P/E ratio 2023 -7,85x
Yield 2023 -
Capitalization 164 M 128 M 128 M
Capi. / Sales 2022 1 316x
Capi. / Sales 2023 38,7x
Nbr of Employees 13
Free-Float 69,7%
More Financials
Company
Medicenna Therapeutics Corp. is an immunotherapy company. The Company is engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) tunable cytokines, called Superkines and Empowered Superkines (ECs). It focuses on commercialization of EC and Superkines for the treatment of cancer and other diseases. The CompanyÔÇÖs Bi-functional SuperKine... 
Sector
Biotechnology & Medical Research
Calendar
09/20 | 03:45pmPresentation
More about the company
Ratings of Medicenna Therapeutics Corp.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about MEDICENNA THERAPEUTICS CORP.
09/20MEDICENNA THERAPEUTICS : Announces Issuance of U.S. Patent Providing Added Intellectual Pr..
PU
09/20MEDICENNA THERAPEUTICS : Announces U.S. Patent Providing Added IP Protection For MDNA11 Pr..
MT
09/20MEDICENNA THERAPEUTICS : Announces Issuance of U.S. Patent Providing Added Intellectual Pr..
AQ
09/14MEDICENNA THERAPEUTICS : Doses First Patient in MDNA11 Phase 1/2 ABILITY Study (Form 6-K)
PU
09/14MEDICENNA THERAPEUTICS : Dual Listed Medicenna Therapeutics Doses First Patient in MDNA11 ..
MT
09/14Medicenna Therapeutics Corp. Doses First Patient in MDNA11 Phase 1/2 Ability Study
CI
09/14MEDICENNA THERAPEUTICS : Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
AQ
09/09MEDICENNA THERAPEUTICS : to Present at Upcoming September Investor Conferences (Form 6-K)
PU
09/09MEDICENNA THERAPEUTICS : to Present at Upcoming September Investor Conferences
AQ
09/01MEDICENNA THERAPEUTICS : Notice and Management Information Circular (Form 6-K)
PU
08/25MEDICENNA THERAPEUTICS : 2021 Management Information Circular
PU
08/16MEDICENNA THERAPEUTICS : Reports First Quarter Fiscal 2022 Financial Results and Operation..
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/13MEDICENNA THERAPEUTICS : Dual Listed Medicenna Therapeutics Reports Q1 Net Loss $6.4 milli..
MT
08/13MEDICENNA THERAPEUTICS : Q1 Management's Discussion & Analysis
PU
More news
News in other languages on MEDICENNA THERAPEUTICS CORP.

- No features available -

More news
Analyst Recommendations on MEDICENNA THERAPEUTICS CORP.
More recommendations
Chart MEDICENNA THERAPEUTICS CORP.
Duration : Period :
Medicenna Therapeutics Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDICENNA THERAPEUTICS CORP.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 3,06 CAD
Average target price 10,98 CAD
Spread / Average Target 259%
EPS Revisions
Managers and Directors
Fahar Merchant Chairman, President & Chief Executive Officer
Elizabeth Williams Chief Financial Officer & Secretary
Martin Bexon Head-Clinical Development
Kevin Moulder Chief Scientific Officer
Mann Muhsin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDICENNA THERAPEUTICS CORP.-48.57%128
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939